Literature DB >> 21479389

Progress of engineered antibody-targeted molecular imaging for solid tumors (Review).

Hong Zhao1, Kemi Cui, Andrea Muschenborn, Stephen T C Wong.   

Abstract

Engineered antibodies, with their high specificity and affinity for their target antigens, as well as their reduced size and multivalent design, can be tailored to carry radionuclide magnetic, luciferase or fluorescent probes for specific attachment to tissue cells, extracellularly or intracellularly, for PET, SPECT, MRI, optical and ultrasonic imaging. The antigen-specific imaging agents of engineered antibodies have deep tissue penetration, high tissue retention and fast blood clearance, which are desirable properties for the rapid imaging of tumors with high specificity and resolution in pre-clinical or clinical imaging studies.

Entities:  

Year:  2008        PMID: 21479389

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Near-infrared molecular probes for in vivo imaging.

Authors:  Xuan Zhang; Sharon Bloch; Walter Akers; Samuel Achilefu
Journal:  Curr Protoc Cytom       Date:  2012-04

Review 2.  Nanobio applications of quantum dots in cancer: imaging, sensing, and targeting.

Authors:  Ahmad SalmanOgli
Journal:  Cancer Nanotechnol       Date:  2011-07-13

3.  Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time.

Authors:  Geoffrey A Sonn; Andrew S Behesnilian; Ziyue Karen Jiang; Kirstin A Zettlitz; Eric J Lepin; Laurent A Bentolila; Scott M Knowles; Daniel Lawrence; Anna M Wu; Robert E Reiter
Journal:  Clin Cancer Res       Date:  2015-10-21       Impact factor: 12.531

4.  Fluorogen activating protein-affibody probes: modular, no-wash measurement of epidermal growth factor receptors.

Authors:  Yi Wang; Cheryl A Telmer; Brigitte F Schmidt; Josef D Franke; Stephan Ort; Donna J Arndt-Jovin; Marcel P Bruchez
Journal:  Bioconjug Chem       Date:  2014-12-19       Impact factor: 4.774

Review 5.  Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.

Authors:  Yaozhong Hu; Changxiao Liu; Serge Muyldermans
Journal:  Front Immunol       Date:  2017-11-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.